Sunshine Biopharma Inc (SBFM)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Sunshine Biopharma Inc Stock (SBFM) Company Profile

Sunshine Biopharma Inc

Healthcare (1170)

954-515-0810

333 LAS OLAS WAY, FORT LAUDERDALE

Nächster Verdiensttermin

Neueste SEC-Einreichungen

SBFM's Discussions on Twitter

Vergleichen Sie SBFM mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SBFM Sunshine Biopharma Inc	1.51	6.52M	32.96M	-4.23M	-14.00M	-155.33
ZTS Zoetis Inc	170.16	75.08B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	11.07	51.07B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.96	46.95B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	17.77	19.24B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	325.82	14.38B	2.99B	1.21B	1.13B	25.06

Sunshine Biopharma Inc Aktie (SBFM) Neueste Nachrichten

Finanzdaten der Sunshine Biopharma Inc-Aktie (SBFM)

Sunshine Biopharma Inc (SBFM)

Sunshine Biopharma Inc Stock (SBFM) Company Profile

Vergleichen Sie SBFM mit anderen Aktien

Sunshine Biopharma Inc Aktie (SBFM) Neueste Nachrichten

Sunshine Biopharma (NASDAQ:SBFMW) Trading 17.8% Higher – Here’s Why - Defense World

Sunshine Biopharma Sees 18% Revenue Growth in Q1 2025 - TipRanks

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues - GuruFocus

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year - ACCESS Newswire

Sunshine Biopharma Reports Double-Digit Growth: Q1 Revenue Jumps 18% as Pipeline Expands with 6 New Drugs - Stock Titan

Sunshine Biopharma (NASDAQ:SBFM) Stock Price Up 8% – Here’s Why - Defense World

Sunshine Biopharma launches generic antipsychotic drug - Investing.com Australia

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia - GuruFocus

Sunshine Biopharma (SBFM) Unveils Generic Antipsychotic Drug in Canada | SBFM Stock News - GuruFocus

Sunshine Biopharma launches generic antipsychotic drug By Investing.com - Investing.com Canada

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market - ACCESS Newswire

Sunshine Biopharma Challenges $1.2B Antipsychotic Market With New Generic Latuda Alternative - Stock Titan

Certain Warrants of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2025. - marketscreener.com

Sunshine Biopharma Inc’s Market Journey: Closing Weak at 1.84, Down -18.22 - DWinneX

Sunshine Biopharma (NASDAQ:SBFMW) Stock Price Down 4.5% – Here’s Why - Defense World

There is no doubt that Sunshine Biopharma Inc (SBFM) ticks all the boxes. - Sete News

Sunshine Becomes Latest To Compete On Everolimus In Canada - insights.citeline.com

Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug - Asianet Newsable

Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug By Stocktwits - Investing.com India

SBFM Stock: A Comprehensive Analysis and Forecast - investchronicle.com

Sunshine Biopharma enters Canadian generic drug market with Everolimus By Investing.com - Investing.com South Africa

Press Release Distribution & PR Platform - ACCESS Newswire

SBFM’s valuation metrics: A comprehensive analysis - uspostnews.com

Sunshine Biopharma (SBFM) Finalizes $2.46 Million Stock Offering - GuruFocus

Sunshine Biopharma Unit Rolls Out Afinitor Alternative Everolimus in Canadian Market - marketscreener.com

Sunshine Biopharma enters Canadian generic drug market with Everolimus - Investing.com

Sunshine Biopharma (SBFM) Launches Generic Everolimus in Canada | SBFM Stock News - GuruFocus

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion | SBFM Stock News - GuruFocus

Major Cancer Treatment Everolimus Enters Canadian Market: Multiple Cancer Types Targeted in $2.5B Opportunity - Stock Titan

Sunshine Biopharma (SBFM) Launches Generic Everolimus in Canada - GuruFocus

Sunshine Biopharma stock hits 52-week low at $1.24 - Investing.com Australia

Sunshine Biopharma stock hits 52-week low at $1.24 By Investing.com - Investing.com India

Sunshine Biopharma (NASDAQ:SBFMW) Trading Down 10.9% – Here’s Why - Defense World

Sunshine Biopharma stock hits 52-week low at $1.85 amid steep decline By Investing.com - Investing.com South Africa

Sunshine Biopharma Closes $2.46 Million Direct Offering - TipRanks

Sunshine Biopharma Secures $2.46 Million in Direct Offering - TipRanks

Sunshine Biopharma Closes $2.5 Million Direct Offering - MarketScreener

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering - ACCESS Newswire

SEC Form 424B5 filed by Sunshine Biopharma Inc. - Quantisnow

Sunshine Biopharma stock hits 52-week low at $1.85 amid steep decline - Investing.com India

Sunshine Biopharma’s K1.1-mRNA-LNP shows promise in HCC mouse model - BioWorld MedTech

The time has not yet come to remove your chips from the table: Sunshine Biopharma Inc (SBFM) - Sete News

Sunshine Biopharma secures $2.46 million in stock offering By Investing.com - Investing.com Canada

Sunshine Biopharma Reports 78% Revenue Growth and Key Developments in 2022 - TipRanks

Sunshine Biopharma (SBFM) Reports Increased Revenue Despite Net Loss - GuruFocus

Sunshine Biopharma (SBFM) Secures $2.46 Million in Direct Stock Offering - GuruFocus

Sunshine Biopharma secures $2.46 million in stock offering - Investing.com

Finanzdaten der Sunshine Biopharma Inc-Aktie (SBFM)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie SBFM